@article{99da080a2f174c9bbfb430c7de2c8749,
title = "Insulin Sensitivity and Diabetic Kidney Disease in Children and Adolescents With Type 2 Diabetes: An Observational Analysis of Data From the TODAY Clinical Trial",
abstract = "Background Diabetic kidney disease is a major cause of premature mortality in type 2 diabetes mellitus (T2DM). Worsening insulin sensitivity independent of glycemic control may contribute to the development of diabetic kidney disease. We investigated the longitudinal association of insulin sensitivity with hyperfiltration and increased albumin excretion in adolescents with T2DM. Study Design Observational prospective cohort study. Setting & Participants 532 TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) participants aged 12 to 17 years with T2DM duration less than 2 years at baseline. The TODAY Study was a multicenter randomized clinical trial that examined the efficacy of 3 treatment regimens (metformin monotherapy, metformin plus rosiglitazone, or metformin plus an intensive lifestyle intervention program) to achieve durable glycemic control. Predictors Natural log–transformed estimated insulin sensitivity (reciprocal of fasting insulin), hemoglobin A1c concentration, age, race-ethnicity, treatment group, body mass index, loss of glycemic control, and hypertension. Outcomes Hyperfiltration was defined as 99th percentile or higher of estimated glomerular filtration rate (≥140 mL/min/1.73 m2) when referenced to healthy adolescents (NHANES 1999-2002) and albumin-creatinine ratio ≥ 30 μg/mg at 3 consecutive annual visits. Results Hyperfiltration was observed in 7.0% of participants at baseline and in 13.3% by 5 years, with a cumulative incidence of 5.0% over 5 years. The prevalence of increased albumin excretion was 6% at baseline and 18% by 5 years, with a cumulative incidence of 13.4%. There was an 8% increase in risk for hyperfiltration per 10% lower estimated insulin sensitivity in unadjusted and adjusted models (P = 0.01). Increased albumin excretion was associated with hemoglobin A1c concentration, but not estimated insulin sensitivity. Limitations Longer follow-up is needed to capture the transition from hyperfiltration to rapid glomerular filtration rate decline in youth-onset T2DM. Conclusions Lower estimated insulin sensitivity was associated with risk for hyperfiltration over time, whereas increased albumin excretion was associated with hyperglycemia in youth-onset T2DM.",
keywords = "Type 2 diabetes mellitus (T2DM), adolescents, albumin-creatinine ratio (ACR), children, creatinine, cystatin C, diabetic kidney disease (DKD), disease progression, estimated glomerular filtration rate (eGFR), hyperfiltration, increased albumin excretion, insulin sensitivity, kidney function, youth-onset T2DM",
author = "{TODAY Study Group} and Petter Bjornstad and Edward Nehus and {El ghormli}, Laure and Fida Bacha and Libman, {Ingrid M.} and Siripoom McKay and Willi, {Steven M.} and Lori Laffel and Silva Arslanian and Nadeau, {Kristen J.} and S. McKay and M. Haymond and B. Anderson and C. Bush and S. Gunn and H. Holden and Jones, {S. M.} and G. Jeha and S. McGirk and S. Thamotharan and L. Cuttler and E. Abrams and T. Casey and W. Dahms and C. Ievers-Landis and B. Kaminski and M. Koontz and S. MacLeish and P. McGuigan and S. Narasimhan and M. Geffner and V. Barraza and N. Chang and B. Conrad and D. Dreimane and S. Estrada and L. Fisher and E. Fleury-Milfort and S. Hernandez and B. Hollen and F. Kaufman and E. Law and V. Mansilla and D. Miller and C. Mu{\~n}oz and R. Ortiz and A. Ward and K. Wexler and Xu, {Y. K.} and O. Hardy",
note = "Funding Information: Support: This work was completed with funding from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)/National Institutes of Health grant numbers T32-DK063687 , U01-DK61212 , U01-DK61230 , U01-DK61239 , U01-DK61242 , and U01-DK61254 ; the National Center for Research Resources (NCRR) General Clinical Research Centers Program grant numbers M01-RR00036 (Washington University School of Medicine), M01-RR00043-45 (Children{\textquoteright}s Hospital Los Angeles), M01-RR00069 (University of Colorado Denver), M01-RR00084 (Children{\textquoteright}s Hospital of Pittsburgh), M01-RR01066 (Massachusetts General Hospital), M01-RR00125 (Yale University), and M01-RR14467 (University of Oklahoma Health Sciences Center); and from the NCRR Clinical and Translational Science Awards grant numbers UL1-RR024134 (Children{\textquoteright}s Hospital of Philadelphia), UL1-RR024139 (Yale University), UL1-RR024153 (Children{\textquoteright}s Hospital of Pittsburgh), UL1-RR024989 (Case Western Reserve University), UL1-RR024992 (Washington University in St Louis), UL1-RR025758 (Massachusetts General Hospital), and UL1-RR025780 (University of Colorado Denver). NIDDK had no role in study design; collection, analysis, and interpretation of data; and writing the report. Drug and supplies donations in support of the study{\textquoteright}s efforts were received from Becton, Dickinson and Company; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; LifeScan, Inc; Pfizer; Sanofi Aventis. None of these companies had any role in any aspect of the study. Funding Information: We gratefully acknowledge the participation and guidance of the American Indian partners associated with the clinical center located at the University of Oklahoma Health Sciences Center, including members of the Absentee Shawnee Tribe, Cherokee Nation, Chickasaw Nation, Choctaw Nation of Oklahoma, and Oklahoma City Area Indian Health Service. Publisher Copyright: {\textcopyright} 2017 National Kidney Foundation, Inc.",
year = "2018",
month = jan,
doi = "10.1053/j.ajkd.2017.07.015",
language = "English (US)",
volume = "71",
pages = "65--74",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "1",
}